A Phase III randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine (Ice) dependence

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2000375

Funding Status
Active

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Crystalline methamphetamine ('ice') is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug. This clinical trial will examine whether mirtazapine, a newly identified treatment agent for methamphetamine use, can be used safely and effectively in routine clinical care to manage methamphetamine dependence in Australia.

Funded Activity Details

Start Date: 06-12-2020

End Date: 01-01-2025

Funding Scheme: Clinical Trials and Cohort Studies Grants

Funding Amount: $3,923,009.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

amphetamine | clinical trial | medications | substance dependence

Related Links